<DOC>
	<DOCNO>NCT00111475</DOCNO>
	<brief_summary>The purpose study : determine weekly dose demonstrate satisfactory safety profile sustains elevate platelet count within target therapeutic level ( double baseline platelet count within range great equal 50 x 10^9/L less equal 450 x 10^9/L thrombocytopenic subject ITP ; assess Amgen megakaryopoiesis protein 2 [ AMP2 ( AMG 531 ) ] pharmacokinetics ( PK ) thrombocytopenic subject ITP .</brief_summary>
	<brief_title>Evaluating Safety Efficacy AMG531 Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Diagnosis ITP accord American Society Hematology ( ASH ) guideline least 3 month enrollment Have complete least 1 prior treatment ITP The mean 2 platelet count take screen pretreatment period must : *less 30 x 10^9/L subject receive ITP therapy , count great 35 x 10^9/L ; less 50 x 10^9/L subject receive constant dose schedule corticosteroid , count great 55 x 10^9/L Hemoglobin great 10.0 g/dL Written inform consent Any known history bone marrow stem cell disorder Any active malignancy . If prior history cancer basal cell carcinoma cervical carcinoma situ , treatment active disease within 5 year randomization Unstable uncontrolled disease condition relate impacting cardiac function ( e.g. , unstable angina , congestive heart failure [ New York Heart Association ( NYHA ) great class II ] , uncontrolled hypertension [ diastolic great 100 mmHg ] cardiac arrhythmia ) Have 3 follow predispose factor thromboembolic event : *diabetes ; *smoker use oral contraceptive ; *hypercholesteremia ( great 240 mg/dL ) ; *treatment hypertension Known positive test human immunodeficiency virus ( HIV ) infection hepatitis C virus Received treatment ITP ( except constant dose schedule corticosteroid ) within 4 week screen visit Received IVIg WinRho within 2 week screen visit Received hematopoietic growth factor , include IL11 ( NeumegaÂ® ) within 4 week screen visit Past present participation study evaluate PEGrHuMGDF , recombinant human thrombopoietin ( rHuTPO ) relate platelet product Received alkylating agent within 8 week screen visit anticipate use time propose study Received monoclonal antibody ( eg , rituximab ) within 16 week screen visit anticipate use time propose study Less 4 week since receipt therapeutic drug device FDA approve indication screen period Less 2 month since major surgery ( include laparoscopic splenectomy ) Pregnant breast feeding Subjects reproductive potential use adequate contraceptive precaution , judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Immune Thrombocytopenic Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Thrombocytopenic</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>ITP</keyword>
</DOC>